<DOC>
	<DOCNO>NCT01154673</DOCNO>
	<brief_summary>This trial investigate efficacy safety intensify antiretroviral treatment include raltegravir maraviroc early stage HIV infection . With proven efficacy antiviral drug pre- post-clinical trial , would like investigate ability combination raltegravir maraviroc plus standard HAART backbone decrease viral load acutely infect treated HIV infected individual .</brief_summary>
	<brief_title>Effects Intensive cART During Acute/Early HIV Infection</brief_title>
	<detailed_description>The trial prospective , randomize , double-blinded , placebo-controlled study follow-up 5 year . Thirty-two individual present newly diagnose acute early HIV-1 infection describe inclusion criterion enrol , sixteen randomize arm . Individuals randomize one two arm : `` Intensive '' arm standard HAART ( Emtricitabine 200mg /tenofovir 300mg QD + Lopinavir 400mg /ritonavir 100mg BID ) + Raltegravir + Maraviroc `` placebo '' arm standard HAART+ Placebo 48 week . Another group individual diagnose acute early HIV-1 elect forego early treatment follow non-randomized , untreated control . At week 48 , patient inform study result . If result positive intensive treatment group , placebo group offer roll-over intense treatment arm follow open-label cohort five year . Participants may stop treatment time withdraw study . If choose , follow accord standard employ HIV-1 patient Maple Leaf clinic . At five year point , decision terminate treatment make base exist state HIV-1 literature time .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>The major single criterion inclusion study presence confirm acute/early HIV1 infection , define one three follow criterion : 1 . Positive HIV1 antibody test result ( Western blot ) , document negative test result previous six month 2 . Positive weakly positive HIV1 antibody screen ELISA test result , indeterminate evolve confirmatory test result demonstrate HIV1 antigenemia ( p24 antigen test result ) viremia ( HIV1 bDNA ≥ 500 copies/ml ) 3 . Negative HIV1 antibody test result set illness compatible acute seroconversion demonstrate HIV1 antigenemia ( p24 antigen test result ) plasma viremia ( HIV1 bDNA ≥ 500 copies/ml ) Other inclusion criterion : Ages 18 old Ability provide inform consent HIV1 viral load ≥ 5,000 copies/ml 1 . Participants would difficulty participate trial due nonadherence substance abuse 2 . Participants follow abnormal laboratory test result screen : Hemoglobin &lt; 85 g/L Neutrophil count &lt; 750 cells/uL Platelet count &lt; 50,000 cells/L AST ALT &gt; 5X upper limit normal Creatinine &gt; 250 umol/L 3 . Participant malignancy 4 . Participant significant underlying disease ( nonHIV1 ) might impinge upon disease progression death 5 . Participant pregnant try conceive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>